25.80

5.18% 1.27

Pre-market: 25.72 -0.08 -0.31%

Cue Biopharma Inc (CUE)

Overview News Price History Option Chain Financials Discussions Forecast

Cue Biopharma Inc stock is traded at $25.80, with a volume of 78,552. It is up +5.18% in the last 24 hours and up +12.13% over the past month. Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Previous Close:

$24.53

Open:

$24.53

24h Volume:

78,552

Relative Volume:

0.11

Market Cap:

$108.37M

Revenue:

$32.73M

Net Income/Loss:

$-19.52M

P/E Ratio:

-4.6676

EPS:

-5.5275

Net Cash Flow:

$-24.61M

1W Performance:

-11.28%

1M Performance:

+12.13%

6M Performance:

+85.95%

1Y Performance:

+42.86%

1-Day Range:

$24.53

$27.93

1-Week Range:

$23.20

$31.57

52-Week Range:

$4.971

$41.42

Cue Biopharma Inc Stock (CUE) Company Profile

Name

Cue Biopharma Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

617-949-2680

Address

40 GUEST STREET, BOSTON, MA

Employee

Twitter

@cuebiopharma

Next Earnings Date

2026-05-18

Latest SEC Filings

CUE's Discussions on Twitter

Compare CUE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CUE Cue Biopharma Inc	25.80	108.37M	32.73M	-19.52M	-24.61M	-5.5275
VRTX Vertex Pharmaceuticals Inc	450.46	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-24	Initiated	Jefferies	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Nov-21-22	Initiated	Piper Sandler	Overweight
Jan-13-22	Initiated	H.C. Wainwright	Buy
Jan-03-22	Initiated	Craig Hallum	Buy
Nov-24-20	Initiated	Berenberg	Buy
Apr-09-20	Initiated	Stifel	Buy
Jan-28-20	Initiated	BTIG Research	Buy
Jan-22-20	Initiated	JMP Securities	Mkt Outperform

View All

Cue Biopharma Inc Stock (CUE) Latest News

Jun 15, 2026

Cue Biopharma Inc Stock (US22966J1060): Analyst focus after sharp move and oncology pipeline updates - AD HOC NEWS

Jun 15, 2026

Jun 13, 2026

CUE Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Progress in Pre-Revenue StageProfit Announcement - lwvtexas.org

Jun 13, 2026

Jun 11, 2026

Cue Biopharma (CUE) VP and Principal Accounting Officer files initial Form 3 - Stock Titan

Jun 11, 2026

Ray Sumita reports Cue Biopharma (CUE) shares and 109,179-share option - Stock Titan

Jun 11, 2026

Breakeven Is Near for Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) - simplywall.st

Jun 11, 2026

Jun 10, 2026

Cue Biopharma (CUE) director awarded 1,626 stock options at $21.90 strike - Stock Titan

Jun 08, 2026

Daniel A. Camardo joins Cue Biopharma (CUE) board and files Form 3 - Stock Titan

Jun 08, 2026

CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits

Jun 08, 2026

Cue Biopharma, Inc. - MLQ.ai

Jun 08, 2026

CUE stock slips as CEO leaves after just six months in role - MSN

Jun 08, 2026

Jun 06, 2026

Cue Biopharma (CUE) Narrows Slightly as Stock Holds Near Key Support LevelsMoney Flow Index - newsline.com

Jun 06, 2026

Jun 05, 2026

Cue Biopharma Inc stock (US22966J1060): Nasdaq-listed immunotherapy developer after reverse split an - AD HOC NEWS

Jun 05, 2026

Veru And 2 Other Intriguing Penny Stocks To Watch - simplywall.st

Jun 05, 2026

Jun 04, 2026

Cue Biopharma Shareholders Approve 2026 Stock Incentive Plan - The Globe and Mail

Jun 04, 2026

Jun 03, 2026

[Form 4] Cue Biopharma, Inc. Insider Trading Activity - Stock Titan

Jun 03, 2026

Cue Biopharma (NASDAQ: CUE) investors approve warrant share issuance and 2026 stock incentive plan - Stock Titan

Jun 03, 2026

4.09M-share resale registration from CUE private placement (NASDAQ: CUE) - Stock Titan

Jun 03, 2026

Cue Biopharma Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus

Jun 03, 2026

Cue Biopharma, Inc. 8-K SEC Filing Details: Company Information, Exchange, and Security Data (May 29, 2026) - Minichart

Jun 03, 2026